Introduction
============

Cervical cancer (CC) remains the fourth leading cause of cancer-related mortality among women worldwide.[@b1-ott-11-6317] Approximately 527,600 cases of CC were diagnosed, resulting in over 265,700 deaths in 2012 globally.[@b2-ott-11-6317] Despite the fact that the 5-year overall survival (OS) rate for patients with early-stage CC iŝ80%, the 5-year OS for stages IIIA, IIIB and IVA disease is 40%, 42% and 22%, respectively.[@b3-ott-11-6317] Postoperative adjuvant chemo-radiotherapy may improve local control, reduce distant metastasis and prolong OS in high-risk patients.[@b4-ott-11-6317] However, adjuvant chemoradiotherapy may also cause side effects that adversely affect the patients' quality of life. Hence, prognostic markers able to predict survival in patients with CC may prove valuable for individualized treatment.

Long non-coding RNAs (lncRNAs) are a type of non-coding transcript with a length of more than 200 nucleotides.[@b5-ott-11-6317] Accumulating evidence indicates that lncRNAs greatly affect gene expression through chromatin modification, transcriptional and post-transcriptional regulation.[@b6-ott-11-6317],[@b7-ott-11-6317] Aberrant expression of lncRNAs has been extensively demonstrated in several types of cancer.[@b8-ott-11-6317],[@b9-ott-11-6317] LncRNAs have been attracting attention over the past decade, and have prompted a series of studies due to their regulation of multiple CC-related cellular processes, including proliferation, invasion, apoptosis, metastasis and radioresistance.[@b10-ott-11-6317]--[@b14-ott-11-6317] Several researchers have focused on detecting prognostic lncRNAs in CC,[@b15-ott-11-6317]--[@b17-ott-11-6317] and a number of studies have described several prognostic lncRNAs in CC, such as *GAS5*,[@b18-ott-11-6317] *PANDAR*,[@b19-ott-11-6317] *TUG1*,[@b20-ott-11-6317] *MEG3*[@b21-ott-11-6317] and *MALAT1*.[@b22-ott-11-6317] However, the comprehensive strength of a potential lncRNA signature for predicting the prognosis of CC has not been clearly determined. Although a 15-lncRNA signature has been developed to predict the prognosis of patient with CC, that study was only focused on cervical squamous cell carcinoma without including cervical adenocarcinoma, which accounts for \~25% of CC cases.[@b23-ott-11-6317]

In the present study, we screened out the prognostic lncRNAs through investigating lncRNA expression profiles in 287 CC patients from The Cancer Genome Atlas database (TCGA),[@b33-ott-11-6317] and constructed a ten-lncRNA signature to effectively predict survival in CC.

Materials and methods
=====================

Patient datasets
----------------

Clinical information of 287 patients with CC were obtained from TCGA on December 10, 2017. The TCGA CC patients were randomly classified into a 200-sample training dataset and an 87-sample testing dataset. The training samples were used to identify lncRNAs whose expression levels are significantly associated with patients' survival and to construct a prognostic signature (risk score), while the testing samples were used to verify the efficiency of the constructed signature. The detailed clinical information for CC is listed in [Table 1](#t1-ott-11-6317){ref-type="table"}.

LncRNA profile mining
---------------------

The lncRNAs extracted from TCGA and GENCODE were cross-referenced with Ensembl IDs in order to refine the number of lncRNAs. We then normalized the lncRNA expression profiles by log2 transformation. Finally, the expression profiles of 7,923 lncRNAs were obtained.

Generation of a prognostic lncRNA signature
-------------------------------------------

Cox's proportional hazards model, which is commonly employed in survival analysis, was used to model the dependence of survival time on lncRNA expression. Since the number of lncRNAs (7,923) was notably higher than the sample size (200), we adopted the iterative sure independence screening (ISIS) procedure for Cox's model[@b24-ott-11-6317] to detect the most significant lncRNAs. ISIS starts with ranking covariates by the absolute value of their marginal correlation with the response variable and selecting the top ranked covariates, and then it adjusts the selected covariates according to the regression residual iteratively. This is a very efficient variable selection method in an ultra-high dimensional scenario.[@b24-ott-11-6317] In this study, the ISIS procedure was implemented using R package "SIS".[@b25-ott-11-6317]

It needed to be emphasized that only the training dataset was used to screen the survival-associated lncRNAs and to construct the expression-based lncRNA signature. Thus, 200 samples in the entire dataset would be distributed to the training dataset and 87 samples would constitute the hold-out sample which would affect the results of lncRNA selection. How to reduce the effect of this random 'hold-out' on the final lncRNA selection is challenging and has been rather overlooked. In the present study, we adopted a sample partitioning strategy inspired by the Jackknife method,[@b26-ott-11-6317] which was proposed to estimate the properties of an estimator derived from a full sample by systematic partitions of the dataset, whereas what was required here was to find a relatively robust result. Based on similar considerations, we repeatedly (100 times) conducted the Cox-based ISIS procedure described previously and only used a random subset (n=150) of the training data in each repeat. After 100 repeats, we obtained 100 groups of significant lncRNAs. The lncRNAs that appeared in at least one of the groups were listed and then sorted by their frequencies of appearance in the 100 groups. By setting the minimum frequency (count of appearance in the 100 groups ≥3), and the maximum *P*-value (*P*\<0.1) in Cox's univariate regression, some candidate prognostic lncRNAs were selected. Then, with the entire training dataset (n=200), the association of the expression level of these lncRNAs with patient survival was further analyzed through a stepwise multivariate Cox regression. Subsequently, prognostic lncRNAs associated with patient survival were obtained.

Finally, we constructed a prognostic lncRNA signature (risk score) by a linear combination of the expression levels of the prognostic lncRNAs with the multivariate Cox regression coefficients estimated previously as the weights: $$\text{Risk~score} = {\sum_{i - 1}^{N}{expr_{i} \times coef_{i}}}$$where N stands for the number of selected prognostic lncRNAs, *expr~i~* stands for the expression level of the *i*th prognostic lncRNA in each patient, and *coef~i~* is the corresponding regression coefficient estimated by the multivariate Cox regression using training data. With these fixed *coef~i~* (*i*=1, ..., N), risk scores could be calculated for all patients. From the form of the Cox proportional hazard model, it is readily observed that patients with a higher risk score are more likely to have poor rates of survival. Using the median risk score in the training dataset as a threshold, the patients were classified into low-risk and high-risk groups. A flow chart was depicted to show the framework of this part ([Figure 1](#f1-ott-11-6317){ref-type="fig"}).

Statistical analysis
--------------------

Kaplan-Meier survival curves and two-sided log-rank tests were employed to compare the survival differences between the high-risk and low-risk groups by using the R package 'survival'. To further investigate whether the lncRNA signature predicts the OS of CC independently of other clinical factors, multivariate Cox regression and stratified analysis were performed. HRs and 95% CIs were computed. The receiver operating characteristic (ROC) curve analysis was performed to assess the predictive power of the lncRNA signature using the R package 'survivalROC'.[@b27-ott-11-6317] The statistical analyses were conducted using R packages(version 3.4.3).

Functional enrichment analysis
------------------------------

The Spearman's rank correlation coefficient between the expression value of each prognostic lncRNA and that of protein-coding genes was computed to infer the potential functional characteristics of the prognostic lncRNAs. Functional enrichment analysis was conducted using DAVID Bioinformatics Resources (version 6.8).[@b28-ott-11-6317] Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were set on the cut-off criteria of *P*\<0.05 and enrichment score \>1.0.

Results
=======

Identification of prognostic lncRNAs associated with OS of patients with CC in the training dataset
---------------------------------------------------------------------------------------------------

The 287 samples were randomly classified into a training dataset (n=200) and a testing dataset (n=87) ([Table 1](#t1-ott-11-6317){ref-type="table"}). In the training dataset, we used a Cox-based ISIS procedure as previously described in "Materials and methods" to identify the most significant lncRNAs associated with the OS of CC patients.[@b24-ott-11-6317] By setting the minimum appearing frequency (count ≥3) in the 100 selected groups, and the maximum *P*-value (*P*\<0.1) in Cox's univariate regression, a total of 23 lncR-NAs, including three up-regulated (coefficient \>0) and 20 down-regulated (coefficient \<0) lncRNAs, were identified as candidates. After the stepwise multivariate Cox regression, ten lncRNAs were selected; among those, eight lncRNAs were down-regulated, indicating that their high expression was correlated with better survival, while the remaining two lncRNAs were up-regulated, suggesting that their high expression was correlated with poor survival. The univariate Cox-regression results (*P*-value and HR) and multivariate Cox-regression results (coefficient) of these ten prognostic lncRNAs using the whole training set are listed in [Table 2](#t2-ott-11-6317){ref-type="table"}.

Derivation of a ten-lncRNA signature for predicting survival from the training dataset
--------------------------------------------------------------------------------------

We constructed a novel lncRNA signature for survival prediction by using the expression value of each lncRNA weighted by their estimated regression coefficients as follows: risk score = (−0.285× expression level of *AC005906.2*) + (−0.290× expression level of *LINC01727*) + (−0.255× expression level of *AC108868.1*) + (−0.547× expression level of *AC020978*.*4*) + (0.160× expression level of *GNAS*. *AS1*) + (0.570× expression level of *AC012306*.*2*) + (−0.351× expression level of *AC024270*.*5*) + (−0.410 × expression level of *AC122694*.*1*) + (−0.356× expression level of *AC015819*.*2*) + (−0.716× expression level of *AL590068*.*1*). Risk scores were calculated and ranked for the 200 samples in the training dataset. The median of the risk scores (0.447957) was used as a threshold to stratify the 200 training samples into a low-risk group (n=100) and a high-risk group (n=100). The Kaplan-Meier analysis revealed that survival of patients in the low-risk group was longer than the high-risk group (31.82 vs 17.62 months, respectively; *P*=1.71E-10; [Figure 2A](#f2-ott-11-6317){ref-type="fig"}). Moreover, the ROC curve analysis acquired an area under the curve (AUC) of 0.852 at 5 years, indicating their significant prognostic performance ([Figure 2B](#f2-ott-11-6317){ref-type="fig"}). The distribution of the risk scores, survival status and expression profiles of the prognostic lncRNAs in the training dataset are presented in [Figure 2C](#f2-ott-11-6317){ref-type="fig"}. It can be seen that patients with high-risk scores have poorer prognosis than patients with low-risk scores. The results of the univariate Cox regression analysis revealed that the ten-lncRNA risk score was significantly associated with patients' OS in the training dataset (*P*=1.74E-08, HR =7.149, 95% CI =3.607--14.170; [Table 3](#t3-ott-11-6317){ref-type="table"}).

Further validation of the ten-lncRNA signature for survival prediction in the testing and the entire datasets
-------------------------------------------------------------------------------------------------------------

To validate our findings, risk scores were calculated for each of the 87 patients in the testing dataset, dividing them into a high-risk group (n=56) and a low-risk group (n=31), according to the previously mentioned risk score model and the threshold derived from the training dataset. In accordance with the findings in the training dataset, patients with high-risk scores had markedly worse OS compared with those with low-risk scores (*P*=1.06E-02, median 20.63 vs 38.97 months, respectively; [Figure 3A](#f3-ott-11-6317){ref-type="fig"}). As shown in [Figure 3C](#f3-ott-11-6317){ref-type="fig"}, the ROC curve analysis yielded an AUC of 0.743 at 5 years in the testing dataset. The HR of the high-risk vs low-risk group for OS was 3.820 (*P*=1.68E-02, 95% CI =1.273--11.460; [Table 3](#t3-ott-11-6317){ref-type="table"}), suggesting that the association of the ten-lncRNA risk score and OS was also significant. Similar findings were observed in the entire dataset, which consisted of 156 high-risk patients with a median OS of 18.5 months and 131 low-risk patients with a median OS of 32.87 months (*P*=1.13E-10; [Figure 3B](#f3-ott-11-6317){ref-type="fig"}). The ROC analysis for the ten-lncRNA achieved an AUC of 0.837 ([Figure 3D](#f3-ott-11-6317){ref-type="fig"}). As shown in [Table 3](#t3-ott-11-6317){ref-type="table"}, the ten-lncRNA signature was found to be significantly correlated with patients' survival in the entire dataset (*P*=5.54E-09, HR =5.448, 95% CI =3.081--9.633).

Independence of the prognostic power of the ten-lncRNA signature from other clinical factors
--------------------------------------------------------------------------------------------

As shown in [Table 3](#t3-ott-11-6317){ref-type="table"}, the results demonstrated that the risk score obtained from the ten-lncRNA signature maintained a significant association with OS, with the other three clinical factors serving as covariates in each dataset. However, we also found that stage was significantly associated with OS in all three datasets. Therefore, stratification analysis was required to determine the prognostic power of the ten-lncRNA signature for the CC stage; the entire dataset was stratified into an early-stage group (I and II, n=223) and a late-stage group (III and IV, n=64). Moreover, the ten-lncRNA signature subdivided CC patients into high-risk and low-risk subgroups in each stage. This analysis demonstrated that patients in the high-risk subgroups had significantly shorter OS than those in the low-risk subgroup for both early-stage (*P*=1.31E-09) and late-stage disease (*P*=1.25E-03) ([Figure 4](#f4-ott-11-6317){ref-type="fig"}).

Functional roles of the ten prognostic lncRNAs
----------------------------------------------

In order to understand the functional implication of the ten prognostic lncRNAs in the development of CC, we carried out a functional enrichment analysis to elucidate their roles. We identified 347 protein-coding genes that were significantly correlated with at least one of the ten prognostic lncRNAs (Spearman \|R\| \>0.4). GO and KEGG pathway enrichment analyses were performed with these genes to identify their associated KEGG pathways and GO annotations. GO analysis consisted of three domains, including biological process, molecular function and cellular component. It was demonstrated that these genes were mainly associated with immune response in biological process, receptor activity and binding in molecular function, and plasma membrane in cellular component ([Figure 5A--C](#f5-ott-11-6317){ref-type="fig"}). These genes were also significantly enriched for cell adhesion molecules (CAMs) and nuclear factor kappa B (NF-κB) signaling ([Figure 5D](#f5-ott-11-6317){ref-type="fig"}).

Discussion
==========

In this study, we identified ten lncRNAs that were significantly associated with OS in CC patients. The ten-lncRNA risk score signature demonstrated superior ability to divide CC patients into high-risk and low-risk groups with significantly different OS in each dataset. Further studies indicated that the ten-lncRNA signature is an independent predictor of OS with other clinical factors, including age, stage and histology, taken into account simultaneously. Therefore, we demonstrated that this ten-lncRNA signature is a promising prognostic biomarker in the progression of CC.

To the best of our knowledge, none of the ten prognostic lncRNAs have been reported in literature to date. Therefore, we screened out protein-coding genes that are intensively correlated with the ten lncRNAs (Spearman \|R\| \>0.4) in the entire database. We conducted an integrated analysis to predict the potential biological roles of the ten lncRNAs through those correlating genes in CC. The results demonstrated that the lncRNA may exert their effects through several known GO annotations and KEGG pathways. The biological processes of the genes were mainly associated with immune suppression. Infection by human papillomavirus (HPV), a causative factor of CC, induces a cellular immune response with regulatory T cells and maintains local immune suppression in HPV-associated CC.[@b29-ott-11-6317] These genes were also significantly enriched in CAMs and the NF-κB signaling pathway. Recent studies have found that CAMs were associated with adhesion or signaling status of tumor cells, promoting acquisition of a more invasive phenotype. It is reported that L1CAM may be a helpful prognostic marker to predict locoregional recurrences in CC.[@b30-ott-11-6317] The NF-κB signaling pathway has been found to play a critical role in the pathogenesis and progression of CC.[@b31-ott-11-6317] It was demonstrated that *MAFIP* may also act as a suppressor in CC by restraining the activation of the NF-κB pathway.[@b32-ott-11-6317]

There were several limitations to this study. First, metastasis was not included, as this information was not available for predicting survival. Second, data from TCGA were built on the RNA-Seq technique, and more experimental methods were needed to confirm the results. Third, the exact mechanisms of action of the ten lncRNAs in CC remain to be fully elucidated; further experiments should be designed to explore these mechanisms in future.

Conclusion
==========

In the present study we identified a ten-lncRNA signature that may prove to be a critical prognostic tool for patients with CC. These lncRNAs modulate genes associated with immune response, CAMs and NF-κB signaling, which has previously been associated with CC tumorigenesis. Ultimately, we expect this lncRNA signature to be helpful for predicting prognosis and uncovering the mechanisms underlying CC development.
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![Flow chart of the prognostic lncRNA signature generation.\
**Notes:** N stands for the number of selected prognostic lncRNAs, *expr~i~* stands for the expression level of the ith prognostic lncRNA in each patient, and *coef~i~* is the corre sponding regression coefficient estimated by the multivariate Cox regression using training data. With these fixed *coef~i~* (*i*=1, ..., N), risk scores could be calculated for all patients.\
**Abbreviations:** ISIS, iterative sure independence screening; lncRNAs, long non-coding RNAs.](ott-11-6317Fig1){#f1-ott-11-6317}

![Association between the ten-lncRNA expression signature and overall survival of patients with CC in the training dataset.\
**Notes:** (**A**) Kaplan-Meier curve of the survival of the CC patients within high-risk and low-risk groups. (**B**) ROC analysis for the performance of the risk score in survival prediction in the training dataset. The AUC was calculated for the ROC curve. (**C**) The ten-lncRNA based risk score distribution, patients' survival status and heatmap of the ten lncRNA expression profiles.\
**Abbreviations:** AUC, area under the curve; cc, cervical cancer; lncRNA, long non-coding RNA; ROC, receiver operating characteristic.](ott-11-6317Fig2){#f2-ott-11-6317}

![The ten-lncRNA related risk score predicts overall survival of patients with CC in the testing dataset and the entire dataset.\
**Notes:** (**A**) Kaplan-Meier curve of the survival of the CC patients using the ten-lncRNA signature in the testing dataset (n=87). (**B**) Kaplan-Meier curve of the survival of the CC patients using the ten-lncRNA-signature in the entire dataset (n=287). (**C**) The ROC analysis for the performance of the risk score in survival prediction in the testing dataset. The AUC was calculated for ROC curves. (**D**) The ROC analysis for the performance of the risk score in survival prediction in the entire dataset. The AUC was calculated for ROC curves.\
**Abbreviations:** AUC, area under the curve; CC, cervical cancer; lncRNA, long non-coding RNA; ROC, receiver operating characteristic.](ott-11-6317Fig3){#f3-ott-11-6317}

![Survival prediction, stratified by stage, of the lncRNA signature in patients.\
**Note:** Kaplan-Meier estimators of the overall survival for patients in two groups with early stage (**A**) and late stage (**B**) cervical cancer.](ott-11-6317Fig4){#f4-ott-11-6317}

![Gene Ontology and pathway analysis of protein-coding genes correlated with prognostic lncRNAs in the signature.\
**Notes:** (**A**--**C**) Top 10 Gene Ontology terms in three domains of the protein-coding genes. The pie plot presents the number of genes in each term. (**D**) Top 20 pathways of protein-coding genes. Risk factors = enrichment levels. The magnitude of the pots = numbers of genes. The color classification = *P*-value.\
**Abbreviation:** lncRNAs, long non-coding RNA.](ott-11-6317Fig5){#f5-ott-11-6317}

###### 

Clinical information of patients with cervical cancer

  Characteristics    Training dataset   Testing dataset   Entire dataset
  ------------------ ------------------ ----------------- ----------------
                                                          
  **Vital status**                                        
  Alive              150 (75.0%)        65 (74.7%)        215 (74.9%)
  Dead               50 (25.0%)         22 (25.3%)        72 (25.1%)
  **Age (years)**                                         
  ≤50                122 (61.0%)        58 (66.7%)        180 (62.7%)
  \>50               78 (39.0%)         29 (33.3%)        107 (37.3%)
  **Histology**                                           
  Non-CSCC           34 (17.0%)         17 (19.5%)        51 (17.8%)
  CSCC               166 (83.0%)        70 (80.5%)        236 (82.2%)
  **Stage**                                               
  I                  111 (55.5%)        48 (55.2%)        159 (55.4%)
  II                 48 (24.0%)         16 (18.4%)        64 (22.3%)
  III                27 (13.5%)         15 (17.2%)        42 (14.6%)
  IV                 14 (7.0%)          8 (9.2%)          22 (7.7%)

**Note:** Data from National Cancer Institute \[home page on the Internet\]. The Cancer Genome Atlas. Available from: <https://cancergenome.nih.gov/>.[@b33-ott-11-6317]

**Abbreviation:** CSCC, cervical squamous cell carcinoma.

###### 

Detailed information of ten prognostic lncRNAs significantly associated with overall survival in patients with cervical cancer

  Ensembl ID        Gene symbol    Chromosomal position        *P*-value   Hazard ratio   Coefficient
  ----------------- -------------- --------------------------- ----------- -------------- -------------
                                                                                          
  ENSG00000256654   *AC005906.2*   chr12:4909867--5026012      2.15E-02    0.434          −0.285
  ENSG00000279082   *LINC01727*    chr20:21570024--21615722    6.92E-04    0.546          −0.290
  ENSG00000231505   *AC108868.1*   chr2:106521903--106538079   3.86E-02    0.512          −0.255
  ENSG00000260891   *AC020978.4*   chr16:68212401--68221671    2.91E-03    0.661          −0.547
  ENSG00000235590   *GNAS.AS1*     chr20:58818918--58850903    4.97E-04    1.665          0.160
  ENSG00000272667   *AC012306.2*   chr2:127931327--127931440   1.15E-02    1.501          0.570
  ENSG00000260608   *AC024270.5*   chr15:83012661--83061845    6.29E-03    0.670          −0.351
  ENSG00000250122   *AC122694.1*   chr5:45890216--45895970     2.12E-02    0.583          −0.410
  ENSG00000278607   *AC015819.2*   chr18:75070197--75071091    1.61E-04    0.546          −0.356
  ENSG00000228800   *AL590068.1*   chr10:30553854--30554483    8.52E-03    0.568          −0.716

###### 

Univariate and multivariate Cox regression analyses in each dataset

  Variables                Univariate analysis   Multivariate analysis                                       
  ------------------------ --------------------- ----------------------- ---------- -------- --------------- ----------
                                                                                                             
  **Training dataset**                                                                                       
  **(n**=**200)**                                                                                            
  Nine-lncRNA risk score                                                                                     
  Low risk/high risk       7.149                 3.607--14.170           1.74E-08   11.997   5.650--25.474   1.00E-10
  Age (years)                                                                                                
  ≤50/\>50                 1.354                 0.776--2.361            0.286      1.311    0.729--2.357    0.366
  Stage                                                                                                      
  I+II/III+IV              2.281                 0.310--2.660            7.82E-03   4.930    2.465--9.861    6.46E-06
  Histology                                                                                                  
  Non-CSCC/CSCC            0.655                 0.335--1.283            0.217      1.141    0.567--2.296    0.711
  **Testing dataset**                                                                                        
  **(n**=**87)**                                                                                             
  Nine-lncRNA risk score                                                                                     
  Low risk/high risk       3.820                 1.273--11.460           1.68E-02   5.449    3.647--14.351   7.05E-05
  Age (years)                                                                                                
  ≤50/\>50                 1.154                 0.480--2.772            0.749      1.007    0.385--2.635    0.988
  Stage                                                                                                      
  I+II/III+IV              2.598                 1.114--6.059            2.71E-02   4.251    2.580--9.391    3.74E-03
  Histology                                                                                                  
  Non-CSCC/CSCC            0.802                 0.291--2.206            0.669      1.380    0.470--4.056    0.558
  **Entire dataset**                                                                                         
  **(n**=**287)**                                                                                            
  Nine-lncRNA risk score                                                                                     
  Low risk/high risk       5.448                 3.081--9.633            5.54E-09   6.171    3.457--11.017   7.47E-10
  Age (years)                                                                                                
  ≤50/\>50                 1.294                 0.813--2.059            0.277      1.357    0.836--2.204    0.217
  Stage                                                                                                      
  I+II/III+IV              2.358                 1.450--3.836            5.47E-04   2.451    1.461--4.113    6.84E-04
  Histology                                                                                                  
  Non-CSCC/CSCC            1.057                 0.555--2.013            0.866      1.127    0.580--2.192    0.724

**Abbreviation:** CSCC, cervical squamous cell carcinoma.
